Table III.
IC50 values of anticancer agents against each ALL-derived F-PDX model.
| ALL-derived F-PDX Medium | DLEU002 RPMI | DLEU003 StemSpan | DLEU005 RPMI | DLEU006 RPMI | DLEU009 RPMI | DLEU012 RPMI | DLEU016 RPMI | DLEU026 RPMI | DLEU031 StemSpan |
|---|---|---|---|---|---|---|---|---|---|
| Anticancer agent | |||||||||
| Prednisolone | 0.165 | >20 | >20 | 0.183 | 0.045 | 0.234 | 0.038 | >20 | 1.656 |
| Cytarabine | 0.833 | 2.632 | 15.210 | >20 | 4.868 | 3.312 | 0.015 | >20 | 0.263 |
| Doxorubicin | 0.019 | 0.385 | 0.034 | 0.020 | 0.041 | 0.105 | 0.017 | 1.092 | 0.064 |
| Mitoxantrone | 0.001 | 0.191 | 0.002 | 0.001 | 0.002 | 0.037 | 0.001 | 0.189 | 0.005 |
| Bleomycin | 9.760 | >20 | 9.991 | 0.146 | 0.151 | >20 | 3.785 | >20 | 5.103 |
| Clofarabine | 0.045 | >20 | 0.069 | >20 | 0.039 | >20 | 0.024 | >20 | 0.040 |
| Dasatinib | 4.647 | >20 | 11.144 | 0.069 | 3.047 | 19.186 | 0.361 | >20 | >20 |
| Daunorubicin | 0.004 | 0.164 | 0.012 | 0.004 | 0.009 | 0.194 | 0.006 | 0.431 | 0.025 |
| Idarubicin | 0.002 | 0.119 | 0.006 | 0.002 | 0.004 | 0.056 | 0.004 | 0.090 | 0.013 |
| Tretinoin | >20 | >20 | >20 | >20 | >20 | 17.978 | 14.233 | >20 | >20 |
| Vincristine | 0.012 | 0.822 | 0.032 | 17.235 | 0.028 | 0.125 | 0.001 | >20 | 0.114 |
| Imatinib | 19.322 | >20 | >20 | 16.640 | 14.286 | >20 | 13.756 | >20 | >20 |
| Nelarabine | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
IC50 values are indicated in µM. F-PDX, Fukushima-patient-derived tumor xenograft; ALL, acute lymphocytic leukemia.